Longitudinal study of depression, anxiety, irritability, and stress in pregnancy following evidence-based counseling on the use of antidepressants
- PMID: 17242590
- DOI: 10.1097/00131746-200701000-00005
Longitudinal study of depression, anxiety, irritability, and stress in pregnancy following evidence-based counseling on the use of antidepressants
Abstract
Background: Pregnant women who suffer from clinical depression and use antidepressant medications may receive conflicting information about fetal safety. Little information exists on the effect of continuation of antidepressants on depressive symptoms during pregnancy.
Objectives: To determine the effectiveness of maintaining antidepressants during pregnancy, as measured by changes in symptoms of depression, anxiety, irritability, and stress following reassuring evidence-based counseling.
Methods: Depressed women who were pregnant and taking antidepressants, and who called the Motherisk program for advice, participated in a study that involved reassuring evidence-based counseling on the risk of antidepressants in pregnancy, followed by four telephone interviews: one in each trimester and one in the postpartum period. Depression, anxiety, irritability, and stress scales were completed at each call.
Results: Of the 58 women who enrolled in the study, 38 completed 75% of the follow-ups. Eight women (14%) discontinued their medication during the study. Depression scores were highest at enrollment in the first trimester and decreased as pregnancy progressed. When data from all women, regardless of dose adjustments, were analyzed, no statistically significant differences were seen between depression scores at any time point; mean depression scores were below the cut off for depression throughout the study period. Irritability, anxiety, and stress scores were not found to be statistically different at any time point during the study.
Conclusion: Evidence-based reassurance and continuous antidepressant pharmacotherapy during gestation can provide pregnant women with effective symptom control for their depression. Women should consult their healthcare provider to ensure that they are being treated effectively; a risk/benefit assessment should be conducted on a case-by-case basis.
Similar articles
-
Negative impact of non-evidence-based information received by women taking antidepressants during pregnancy from health care providers and others.J Obstet Gynaecol Can. 2012 Jan;34(1):66-71. doi: 10.1016/S1701-2163(16)35136-2. J Obstet Gynaecol Can. 2012. PMID: 22260766
-
Use of antidepressants by pregnant women: evaluation of perception of risk, efficacy of evidence based counseling and determinants of decision making.Arch Womens Ment Health. 2005 Nov;8(4):214-20. doi: 10.1007/s00737-005-0094-8. Epub 2005 Jun 17. Arch Womens Ment Health. 2005. PMID: 15959622
-
Impact of antidepressant use, discontinuation, and dosage modification on maternal depression during pregnancy.Eur Neuropsychopharmacol. 2019 Jul;29(7):803-812. doi: 10.1016/j.euroneuro.2019.06.007. Epub 2019 Jun 24. Eur Neuropsychopharmacol. 2019. PMID: 31248651
-
Pharmacotherapy of depression in pregnancy.Ann Clin Psychiatry. 2004 Apr-Jun;16(2):87-100. doi: 10.1080/10401230490453662. Ann Clin Psychiatry. 2004. PMID: 15328902 Review.
-
Depression During Pregnancy and Postpartum.Curr Psychiatry Rep. 2016 Mar;18(3):32. doi: 10.1007/s11920-016-0664-7. Curr Psychiatry Rep. 2016. PMID: 26879925 Review.
Cited by
-
Practitioner review: maternal mood in pregnancy and child development--implications for child psychology and psychiatry.J Child Psychol Psychiatry. 2014;55(2):99-111. doi: 10.1111/jcpp.12153. Epub 2013 Oct 16. J Child Psychol Psychiatry. 2014. PMID: 24127722 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous